

# TAKE LIFE ON

The information presented is based on the US label and is not consistent with the Canadian label. This material is intended to be used at the ISTH 2023 Congress only.

**Refixia® once-weekly for routine prophylaxis, on-demand treatment, and perioperative management of bleeds<sup>1</sup> gives your adult AND paediatric patients the confidence to live beyond haemophilia B<sup>2-5</sup>**

Learn more about how Refixia® can help your patients at the **Refixia® Product Theatre:**

## MORE AMBITIOUS PROPHYLAXIS FOR ALL HAEMOPHILIA B PATIENTS: WHY AND HOW?

**June 26<sup>th</sup> 2023**  
**12:15–13:00 (EST)**  
**Presentation Theatre 3**

### AGENDA

12:15	<b>Welcome and introduction</b>	Dr. Stephanie Seremetis
12:20	<b>All patients with haemophilia B regardless of severity can benefit from high FIX levels</b>	Prof. Anthony Chan
12:35	<b>How Refixia® will help address the unmet needs of haemophilia B, leading to improved treatment outcomes</b>	Dr. Stephanie Seremetis
12:50	<b>Panel discussion and meeting closure</b>	All

### SPEAKERS



**Dr. Stephanie Seremetis**

CVP and Chief Medical Officer Rare Disease and Advanced Therapies, Novo Nordisk, Bagsvaerd, Denmark



**Prof. Anthony Chan**

Paediatric Haematologist, McMaster Children's Hospital, Hamilton, Ontario, Canada

Jason, 8 years old, enjoys go-karting and loves to be outdoors. Jason lives with haemophilia B.

The information presented is based on the US label and is not consistent with the Canadian label. This material is intended to be used at the ISTH 2023 Congress only.

## REINVENT LIFE FOR YOUR HAEMOPHILIA B PATIENTS WITH REFIXIA® ONCE-WEEKLY PROPHYLAXIS<sup>2-5</sup>

Refixia® allows for a more ambitious prophylaxis, in line with the World Federation of Hemophilia guidelines:<sup>6</sup>



of the week spent in a non-haemophilic FIX range (>40 IU/dL)<sup>2</sup>

Refixia® prophylaxis allows for an almost bleed-free life with **0 median annualised spontaneous bleeds**<sup>4,7-10</sup> and



target joint resolution<sup>3</sup>

Real-world evidence demonstrates a



reduction in the mean-inpatient ABR after patients switched from standard half-life rFIX to Refixia®\*†11,12

Refixia® prophylaxis provides **bleed-free protection in children** with

0

spontaneous bleeds for patients ≤12 years<sup>13</sup>

ABR, annualised bleed rate; FIX, factor IX; rFIX, recombinant factor IX; rFIXFc, recombinant factor IX-Fc fusion protein.

\* The Canadian Bleeding Disorders Registry (CBDR) collects real-world data for patients with haemophilia.<sup>11,12</sup> Based on a retrospective study on CBDR patients with haemophilia B receiving prophylactic Refixia® for at least 6 months after switching from either rFIXFc or rFIX. Data set contains 5 patients under the age of 18.<sup>12</sup>

† Significant reduction using a binomial regression model.<sup>12</sup>



Jason, 8 years old, enjoys go-karting and loves to be outdoors. Jason lives with haemophilia B.

**References:** 1. Rebinyn® US Prescribing Information. 2022. 2. Tiede A et al. *Haemophilia*. 2017;23(4):547-555. 3. Negrier C et al. *Haemophilia*. 2016;22:507-513. 4. Collins PW et al. *Blood*. 2014;124(26):3880-3886. 5. Young G et al. *Thromb Res*. 2016;141:69-76. 6. World Federation of Hemophilia (WFH). Guidelines for management of hemophilia, 3<sup>rd</sup> edition. Available at: <https://www1.wfh.org/publications/files/pdf-1863.pdf>. Retrieved March 2023. 7. Collins PW. *Haemophilia*. 2012;18 Suppl 4:131-135. 8. Oldenburg J. *Blood*. 2015;125:2038-2044. 9. van Keep M et al. *J Comp Eff Res*. 2018;7:39-48. 10. Jiménez-Yuste V et al. *Blood Transfus*. 2014;12:314-319. 11. Lee et al. *Blood*. 2020;136:37-38. 12. Matino D et al. *Res Pract Thromb Haemost*. 2022;6(e12661). 13. Carcao M et al. *J Thromb Haemost*. 2016;14:1521-1529.



Refixia® and Rebinyn® are registered trademarks owned by Novo Nordisk Health Care AG and the Apis bull logo is a registered trademark owned by Novo Nordisk A/S © 2023 Novo Nordisk Health Care AG, Zürich, Switzerland  
CA23RFX00003

**rebinyn®**  
Coagulation Factor IX  
(Recombinant), PEGylated

**refixia®**  
nonacog beta pegol